Overview | Pre-Conference Short Course | Day 1 | Day 2 | Day 3

Download 2008 Final Brochure

Comprehensive, systematic characterization of the plasma proteome in healthy and diseased states greatly facilitates the development of biosignatures for early disease detection, clinical diagnosis, and therapy. However, blood plasma is the most complex human-derived proteome containing other tissue proteome subsets as well as a wide dynamic range of protein concentrations. Therefore, the characterization of biosignatures in the human plasma proteome is a very complicated task. This is due in part to the lack of a coherent pipeline connecting biosignature discovery with well-established methods for validation. Cambridge Healthtech Institute’s 8th Annual Mining the Plasma Proteome addresses the challenges and strategies of these inherent phases and processes for biosignature discovery and development.

What is the best tool to reach your research goal? Mass Spectrometry, Protein Arrays, Chromatography, Data Analysis and Interpretation?

Advances in methods and technology for profiling plasma proteins now enable construction of a comprehensive pipeline from:

• Candidate discovery

• Qualification

• Verification

• Research assay optimization

• Validation

• Commercialization

Scientific Advisory Committee
N. Leigh Anderson, Ph.D., Founder & CEO, Plasma Proteome Institute
Daniel Chelsky, Ph.D., CSO, Caprion Pharmaceuticals
Jerald S. Feitelson, Ph.D., Business Development Manager, Discovery Products Business Center, Beckman Coulter, Inc.
Karin Hughes, Ph.D., Worldwide Product Director-Sepsis, Stroke & Protein C, , Biosite Inc.
Karin Rodland, Ph.D., Science Lead, NIH Programs, Biological Sciences Division, Pacific Northwest National Laboratory